Secukinumab

Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks. As well as in chronic plaque psoriasis, secukinumab has also been found effective and safe as monotherapy in nail and hairy skin psoriasis and psoriatic arthritis. Secukinumab should be used with caution in patients or their first-degree relatives who have inflammatory bowel disease. It has a safe side effect profile in terms of latent tuberculosis activation.

Sekukinumab

Sekukinumab interlökin-17A’ya yönelik, insan kaynaklý immünoglobulin G1/κ tipinde bir monoklonal antikordur. Klinik araþtýrmalarda PAÞÝ75 yanýtý elde edilen hasta oraný 12. haftada %77 ile 81 arasýnda deðiþmektedir. Kronik plak tip psoriasis yaný sýra týrnak ve saçlý deri psoriasisi ile psoriatik artritte de tek baþýna etkili ve güvenli bulunmuþtur. Kendisinde ya da birinci derece yakýnlarýnda inflamatuar barsak hastalýðý bulunanlarda dikkatli kullaným gerektiren sekukinumab, latent tüberküloz aktivasyonu açýsýndan güvenli bir yan etki profiline sahiptir.